Brief: Bone Biologics And Jeffrey Frelick Entered Into An Amended And Restated Letter Agreement On March 12
15/03/2024 20:52
March 15 (Reuters) - Bone Biologics Corp BBLG.O :
* BONE BIOLOGICS CORP - ON MARCH 12, CO AND JEFFREY FRELICK,
ENTERED INTO AN AMENDED AND RESTATED LETTER AGREEMENT, EFFECTIVE
AS OF JANUARY 1, 2024
* BONE BIOLOGICS CORP - PURSUANT TO FRELICK AGREEMENT,
FRELICK
WILL CONTINUE TO SERVE AS COMPANY'S CHIEF EXECUTIVE OFFICER
Source text for Eikon: ID:n0001493152-24-010114
Further company coverage: BBLG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bone Biologics
See all newsBone Biologics Corp expected to post a loss of 39 cents a share - Earnings Preview
Brief: Bone Biologics Extends Rhnell-1 Shelf Life To 24 Months
Brief: Bone Biologics CEO Issues Letter To Stockholders Highlighting Company Update And Outlook
Bone Biologics Corp expected to post a loss of 53 cents a share - Earnings Preview
Bone Biologics Corp expected to post a loss of 58 cents a share - Earnings Preview